ENDMC
MCID: END057
MIFTS: 68

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 57 12 53 75 37 13 55 15
Endometrial Carcinoma 12 29 13 55 6 15 73
Endometrial Neoplasm 12 29 6
Malignant Neoplasm of Endometrium 12 73
Carcinoma, Endometrioid 44 73
Endometrial Neoplasms 44 73
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 57
Endometrial Carcinoma, Somatic 57
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 57
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Endometrioid Carcinoma 12
Uterine Corpus Cancer 73
Tumor of Endometrium 12
Cancer, Endometrial 40
Endometrial Ca 12
Endmc 75

Classifications:



External Ids:

OMIM 57 608089
Disease Ontology 12 DOID:1380 DOID:2871
ICD10 33 C54.1
SNOMED-CT 68 30289006 93781006
MedGen 42 C0476089
KEGG 37 H00026
SNOMED-CT via HPO 69 254878006

Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 75 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and adenocarcinoma. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Peppermint and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and uterus, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology : 12 A uterine cancer that is located in tissues lining the uterus.

Wikipedia : 76 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.0 CTNNB1 KRAS MLH3 MSH3 MSH6 MUTYH
2 adenocarcinoma 31.0 CDH1 CTNNB1 FGFR2 KRAS PTEN
3 carcinosarcoma 30.8 CTNNB1 KRAS PTEN
4 colorectal cancer 30.7 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
5 ovarian cancer 30.6 CDH1 CTNNB1 GAS5 HOTAIR KRAS LINC-ROR
6 breast cancer 30.6 CASC2 CDH1 CTNNB1 FGFR2 GAS5 HOTAIR
7 uterine carcinosarcoma 30.5 CDH1 CTNNB1 FGFR2 PTEN
8 endometrial adenocarcinoma 30.5 CTNNB1 FGFR2 KRAS PTEN
9 mismatch repair cancer syndrome 30.5 CTNNB1 MSH6 PTEN
10 uterine anomalies 30.3 CDH1 CTNNB1 MSH6 PTEN
11 familial adenomatous polyposis 30.3 CDH1 CTNNB1 KRAS MSH3 MSH6 MUTYH
12 gallbladder cancer 30.3 CDH1 HOTAIR KRAS LINC-ROR TUG1
13 squamous cell carcinoma 30.2 CDH1 CTNNB1 FGFR2 HOTAIR PTEN TUG1
14 cervical cancer 30.1 CDH1 CTNNB1 GAS5 HOTAIR PTEN TUG1
15 myeloma, multiple 30.0 GAS5 HOTAIR KRAS TUG1
16 female reproductive endometrioid cancer 30.0 CTNNB1 PTEN
17 pancreatic cancer 30.0 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
18 melanoma 29.9 GAS5 HOTAIR LINC-ROR MIR200C PTEN
19 lung cancer 29.9 CASC2 CDH1 FGFR2 GAS5 HOTAIR KRAS
20 renal cell carcinoma, nonpapillary 29.9 CASC2 CDH1 GAS5 HOTAIR LINC-ROR MIR200C
21 uterine corpus endometrial carcinoma 12.3
22 fallopian tube endometrioid adenocarcinoma 11.5
23 polycystic ovary syndrome 11.4
24 polycystic ovary syndrome 1 11.4
25 high-grade neuroendocrine carcinoma of the corpus uteri 11.2
26 cervical endometrioid adenocarcinoma 11.1
27 endometrioid ovary carcinoma 11.1
28 cowden syndrome 1 11.1
29 endometrial transitional cell carcinoma 11.1
30 endometrial squamous cell carcinoma 11.1
31 endometrial adenosquamous carcinoma 11.1
32 endometrium carcinoma in situ 11.1
33 precocious puberty, central, 2 11.0
34 colorectal cancer, hereditary nonpolyposis, type 5 11.0
35 precocious puberty, central, 1 11.0
36 lynch syndrome i 11.0
37 colonic disease 10.5 CDH1 CTNNB1 KRAS MSH6
38 colorectal adenocarcinoma 10.5 CDH1 CTNNB1 KRAS MSH6
39 female reproductive system disease 10.5 CDH1 CTNNB1 MSH6 PTEN
40 respiratory system cancer 10.5 CDH1 CTNNB1 KRAS PTEN
41 reproductive system disease 10.5 CDH1 CTNNB1 PTEN
42 endocrine gland cancer 10.5 CDH1 CTNNB1 KRAS PTEN
43 colon adenocarcinoma 10.5 CDH1 CTNNB1 KRAS MSH6
44 intestinal disease 10.4 CDH1 CTNNB1 KRAS MSH6 MUTYH
45 adenoid cystic carcinoma 10.4 CDH1 CTNNB1 KRAS PTEN
46 anaplastic thyroid cancer 10.4 CDH1 CTNNB1 PTEN
47 gastric adenocarcinoma 10.4 CDH1 CTNNB1 FGFR2 HOTAIR KRAS PTEN
48 male reproductive organ cancer 10.4 CDH1 CTNNB1 PTEN
49 cholangiocarcinoma 10.4 CDH1 CTNNB1 KRAS PTEN TUG1
50 intrahepatic cholangiocarcinoma 10.4 CDH1 CTNNB1 FGFR2 KRAS TUG1

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Clinical features from OMIM:

608089

Human phenotypes related to Endometrial Cancer:

32
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 32 HP:0012114

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 KRAS
2 Decreased viability GR00106-A-0 9.55 KRAS
3 Decreased viability GR00221-A-1 9.55 CDH1 KRAS
4 Decreased viability GR00221-A-2 9.55 KRAS
5 Decreased viability GR00301-A 9.55 CDH1 FGFR2 KRAS MLH3
6 Decreased viability GR00342-S-1 9.55 FGFR2
7 Decreased viability GR00342-S-2 9.55 FGFR2
8 Decreased viability GR00342-S-3 9.55 FGFR2
9 Decreased viability GR00381-A-1 9.55 KRAS
10 Decreased viability GR00402-S-2 9.55 CDH1 FGFR2 KRAS MLH3

MGI Mouse Phenotypes related to Endometrial Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 343)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved Phase 4
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 595-33-5 11683
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
4
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
5 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 979-32-8
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
7
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Appetite Stimulants Phase 4,Phase 3,Phase 2,Phase 1
10 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
12
Megestrol Phase 4,Phase 3,Phase 2,Phase 1 3562-63-8 19090 3080587
13 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
14 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3
16 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
19 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Medroxyprogesterone Phase 4,Phase 2,Phase 3,Not Applicable 520-85-4 10631
22 Fluorodeoxyglucose F18 Phase 4,Phase 1,Phase 2,Not Applicable
23 taxane Phase 4,Phase 1,Not Applicable
24 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
26
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
27
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
28
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
29
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
30
Levonorgestrel Approved, Investigational Phase 3,Phase 2,Not Applicable 17489-40-6, 797-63-7 13109
31
Methylene blue Approved, Investigational Phase 3,Not Applicable 61-73-4
32
Progesterone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 57-83-0 5994
33
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
34
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
35
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
36
Epirubicin Approved Phase 3 56420-45-2 41867
37
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
38
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
39
Lenvatinib Approved, Investigational Phase 3,Phase 2,Phase 1 417716-92-8
40
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
41
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
42
Ifosfamide Approved Phase 3 3778-73-2 3690
43
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
44
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
45
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
46
Niraparib Approved, Investigational Phase 2, Phase 3,Phase 1 1038915-60-4 24958200
47
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
48
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763

Interventional clinical trials:

(show top 50) (show all 732)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
4 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
7 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
8 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
9 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
10 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Unknown status NCT02762214 Phase 3
11 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
12 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
13 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
14 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
15 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
16 Atezolizumab Trial in Endometrial Cancer - AtTEnd Recruiting NCT03603184 Phase 3 Atezolizumab;Placebos;Paclitaxel;Carboplatin
17 VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Not yet recruiting NCT03324958 Phase 3
18 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer. Recruiting NCT03555422 Phase 3 Selinexor;Placebo
19 Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer Terminated NCT00016341 Phase 3 cisplatin;doxorubicin hydrochloride;megestrol acetate;paclitaxel;tamoxifen citrate
20 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
21 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
22 Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome Terminated NCT00566644 Phase 3
23 A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Terminated NCT00883116 Phase 3 Ixabepilone;Doxorubicin;Paclitaxel
24 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
25 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
26 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
27 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
28 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
29 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
30 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
31 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
32 Laparoscopic Approach to Cancer of the Endometrium Active, not recruiting NCT00096408 Phase 3
33 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3 conjugated estrogens
34 Regional Anesthesia and Endometrial Cancer Recurrence Withdrawn NCT00531349 Phase 3 Sevoflurane
35 Vaginal Cuff Brachytherapy Fractionation Study Recruiting NCT03785288 Phase 3
36 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
37 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
38 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
39 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Recruiting NCT03517449 Phase 3 Pembrolizumab;Lenvatinib;Paclitaxel;Doxorubicin
40 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Recruiting NCT02598219 Phase 3 Pre-operative SN mapping with radionucleide;Intra-operative SN mapping with patent V blue dye;Intra-operative SN mapping with indocyanin green
41 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
42 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
43 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
44 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
45 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
46 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
47 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Recruiting NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
48 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
49 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
50 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 29 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 29

Anatomical Context for Endometrial Cancer

MalaCards organs/tissues related to Endometrial Cancer:

41
Lymph Node, Breast, Uterus, Testes, Bone, Endothelial, Ovary

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

19
Tissues Lining The Uterus

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 3418)
# Title Authors Year
1
Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. ( 30414437 )
2019
2
Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. ( 30146796 )
2019
3
Xanthogranulomatous endometritis mimicking endometrial carcinoma: A case report and review of literature. ( 30386451 )
2019
4
The International Society of Gynecological Pathologists (ISGyP) Endometrial Carcinoma Project. ( 30550479 )
2019
5
Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP). ( 30550480 )
2019
6
Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists. ( 30550481 )
2019
7
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. ( 30550484 )
2019
8
Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). ( 30550486 )
2019
9
The ability of ADC measurements in the assessment of patients with stage I endometrial carcinoma based on three risk categories. ( 29667881 )
2019
10
Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. ( 29434922 )
2018
11
Clinicopathological and prognostic significance of blood microvessel density in endometrial cancer: a meta-analysis and subgroup analysis. ( 29327157 )
2018
12
Chest wall metastasis of endometrial cancer: case report and review of the literature. ( 29433406 )
2018
13
miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development. ( 29391048 )
2018
14
Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. ( 29417286 )
2018
15
Endometrial cancer follow up; finding the confidence to let go? ( 29978539 )
2018
16
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib. ( 29963728 )
2018
17
Updates on Conservative Management of Endometrial Cancer. ( 28782618 )
2018
18
Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. ( 29426961 )
2018
19
Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. ( 29942724 )
2018
20
Correction to: Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue. ( 29948166 )
2018
21
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. ( 29951943 )
2018
22
Endometrial cancer in the elderly: does patient age influence the choice of treatment interventions and do age-related treatment choices impact survival? ( 29975285 )
2018
23
Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies? ( 29426745 )
2018
24
Folate receptor-I+ targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. ( 29416655 )
2018
25
Contemporary approaches to High-risk, Early-Stage Serous Endometrial Cancer: Clinical Equipoise Persists. ( 29965808 )
2018
26
A small compound spindlactone A sensitizes human endometrial cancer cells to TRAIL-induced apoptosis via the inhibition of NAD(P)H dehydrogenase quinone 1. ( 29950865 )
2018
27
Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. ( 29416671 )
2018
28
Patient-initiated follow-up affects fear of recurrence and health care use: A randomized trial in early-stage endometrial cancer. ( 29978593 )
2018
29
The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )
2018
30
Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )
2018
31
Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. ( 29441458 )
2018
32
miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. ( 29955087 )
2018
33
Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it. ( 29977988 )
2018
34
Blocking 17I^-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. ( 29144553 )
2018
35
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. ( 29439179 )
2018
36
Skeletal Muscle Quality Beyond Average Muscle Attenuation: A Proposal of Skeletal Muscle Phenotypes to Predict Short-Term Survival in Patients With Endometrial Cancer. ( 29439176 )
2018
37
Correction to: SEOM clinical guidelines for endometrial cancer (2017). ( 29417438 )
2018
38
Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model. ( 29300901 )
2018
39
HOTTIP regulates progression of endometrial cancer via activating PI3K/AKT pathway. ( 29949146 )
2018
40
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. ( 29449189 )
2018
41
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. ( 29338923 )
2018
42
HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. ( 29463191 )
2018
43
Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women. ( 29718856 )
2018
44
Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. ( 29922709 )
2018
45
Ultrasound Scoring of Endometrial Pattern for Fast-Track Identification or Exclusion of Endometrial Cancer in Women with Postmenopausal Bleeding. ( 29944932 )
2018
46
Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )
2018
47
Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate. ( 29369118 )
2018
48
Metabolomic Signature of Endometrial Cancer. ( 29235868 )
2018
49
Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway. ( 29449346 )
2018
50
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. ( 29444159 )
2018

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

75
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6 (show top 50) (show all 90)
# Gene Variation Type Significance SNP ID Assembly Location
1 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
2 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
3 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
4 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh38 Chromosome 1, 45331556: 45331556
5 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh37 Chromosome 14, 75514138: 75514138
6 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh38 Chromosome 14, 75047435: 75047435
7 MLH3 NM_001040108.1: c.885delG deletion Pathogenic
8 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847
9 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh38 Chromosome 10, 87931090: 87931090
10 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
11 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh37 Chromosome 5, 79970922: 79970922
12 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh37 Chromosome 16, 68857496: 68857496
13 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh38 Chromosome 16, 68823593: 68823593
14 CDH1 NM_004360.4(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs33935154 GRCh37 Chromosome 16, 68856041: 68856041
15 CDH1 NM_004360.4(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs33935154 GRCh38 Chromosome 16, 68822138: 68822138
16 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
17 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
18 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
19 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
20 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
21 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh38 Chromosome 12, 25245345: 25245345
22 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
23 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh38 Chromosome 10, 121515280: 121515280
24 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
25 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh38 Chromosome 10, 121515289: 121515289
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh38 Chromosome 3, 41224610: 41224610
28 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh37 Chromosome 3, 37090074: 37090074
29 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh38 Chromosome 3, 37048583: 37048583
30 PTEN NM_000314.6(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh37 Chromosome 10, 89690828: 89690828
31 PTEN NM_000314.6(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh38 Chromosome 10, 87931071: 87931071
32 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853
33 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh38 Chromosome 2, 47800714: 47800714
34 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh37 Chromosome 10, 89720731: 89720731
35 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh38 Chromosome 10, 87960974: 87960974
36 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh37 Chromosome 10, 89720741: 89720741
37 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh38 Chromosome 10, 87960984: 87960984
38 ERBB2 NM_001005862.2(ERBB2): c.2416C> T (p.Leu806=) single nucleotide variant not provided rs104886008 GRCh37 Chromosome 17, 37881314: 37881314
39 ERBB2 NM_001005862.2(ERBB2): c.2416C> T (p.Leu806=) single nucleotide variant not provided rs104886008 GRCh38 Chromosome 17, 39725061: 39725061
40 EGFR NM_005228.4(EGFR): c.2544G> A (p.Pro848=) single nucleotide variant not provided rs104886012 GRCh37 Chromosome 7, 55259486: 55259486
41 EGFR NM_005228.4(EGFR): c.2544G> A (p.Pro848=) single nucleotide variant not provided rs104886012 GRCh38 Chromosome 7, 55191793: 55191793
42 EGFR NM_005228.4(EGFR): c.2625+8G> A single nucleotide variant not provided rs104886014 GRCh37 Chromosome 7, 55259575: 55259575
43 EGFR NM_005228.4(EGFR): c.2625+8G> A single nucleotide variant not provided rs104886014 GRCh38 Chromosome 7, 55191882: 55191882
44 BRAF NM_004333.4(BRAF): c.1807C> T (p.Arg603Ter) single nucleotide variant not provided rs104886015 GRCh37 Chromosome 7, 140453128: 140453128
45 BRAF NM_004333.4(BRAF): c.1807C> T (p.Arg603Ter) single nucleotide variant not provided rs104886015 GRCh38 Chromosome 7, 140753328: 140753328
46 PIK3CA NM_006218.3(PIK3CA): c.1540-56C> T single nucleotide variant not provided rs104886002 GRCh37 Chromosome 3, 178935942: 178935942
47 PIK3CA NM_006218.3(PIK3CA): c.1540-56C> T single nucleotide variant not provided rs104886002 GRCh38 Chromosome 3, 179218154: 179218154
48 EGFR NM_005228.4(EGFR): c.2866G> A (p.Asp956Asn) single nucleotide variant not provided rs104886026 GRCh37 Chromosome 7, 55268026: 55268026
49 EGFR NM_005228.4(EGFR): c.2866G> A (p.Asp956Asn) single nucleotide variant not provided rs104886026 GRCh38 Chromosome 7, 55200333: 55200333
50 MSH6 NM_000179.2(MSH6): c.1063G> A (p.Gly355Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587778531 GRCh37 Chromosome 2, 48026185: 48026185

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 4130)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6935601 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 15
2 COSM6982868 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 15
3 COSM6935600 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 15
4 COSM6845183 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2143C>T p.R715* 16:72958003-72958003 15
5 COSM6845177 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7490C>T p.S2497L 16:72795192-72795192 15
6 COSM6845174 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 15
7 COSM6845142 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 15
8 COSM6845190 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 15
9 COSM1709385 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 15
10 COSM3276799 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8299G>A p.G2767R 16:72794383-72794383 15
11 COSM6845133 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 15
12 COSM6845182 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3628C>T p.R1210* 16:72811940-72811940 15
13 COSM6845164 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7666G>C p.A2556P 16:72795016-72795016 15
14 COSM6845156 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 15
15 COSM6845152 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1109G>A p.G370D 16:72959037-72959037 15
16 COSM6845162 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6473G>A p.R2158Q 16:72796209-72796209 15
17 COSM973493 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9001G>T p.E3001* 16:72793681-72793681 15
18 COSM6826430 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 15
19 COSM6845155 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2725G>A p.G909S 16:72950960-72950960 15
20 COSM1233352 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 15
21 COSM6826396 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 15
22 COSM6845159 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3829G>A p.V1277M 16:72811612-72811612 15
23 COSM5563443 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6820C>T p.Q2274* 16:72795862-72795862 15
24 COSM6845186 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 15
25 COSM6984593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6046G>A p.E2016K 16:72796636-72796636 15
26 COSM973492 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 15
27 COSM6984595 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 15
28 COSM6845173 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3863C>T p.T1288M 16:72811578-72811578 15
29 COSM973535 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 15
30 COSM6982810 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4103A>G p.N1368S 16:72798579-72798579 15
31 COSM6845141 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 15
32 COSM6845171 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3115C>T p.H1039Y 16:72950570-72950570 15
33 COSM1640552 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 15
34 COSM6982809 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 15
35 COSM6984596 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1378G>A p.E460K 16:72958768-72958768 15
36 COSM6845169 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 15
37 COSM6845189 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8228A>G p.Y2743C 16:72794454-72794454 15
38 COSM6845185 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5635A>T p.K1879* 16:72797047-72797047 15
39 COSM3276999 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.359G>A p.G120E 16:72959787-72959787 15
40 COSM1379731 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.884G>A p.R295H 16:72959262-72959262 15
41 COSM3276890 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3397G>A p.E1133K 16:72889782-72889782 15
42 COSM6845129 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7559T>C p.L2520P 16:72795123-72795123 15
43 COSM6845179 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 15
44 COSM973560 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 15
45 COSM6845161 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 15
46 COSM6845178 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8197C>A p.R2733S 16:72794485-72794485 15
47 COSM6845188 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6058A>G p.K2020E 16:72796624-72796624 15
48 COSM6984594 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 15
49 COSM6845165 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 15
50 COSM6845127 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 15

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Endometrial cancer hsa05213

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 CDH1 FGFR2 KRAS MSH6 PTEN
2
Show member pathways
12.44 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
3
Show member pathways
12.43 CDH1 CTNNB1 FGFR2 KRAS PTEN
4 11.89 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
5 11.87 CDH1 CTNNB1 KRAS MSH3 MSH6
6 11.76 CTNNB1 KRAS PTEN
7 11.73 CTNNB1 KRAS PTEN
8 11.68 CDH1 CTNNB1 FGFR2
9
Show member pathways
11.64 MLH3 MSH3 MSH6
10 11.54 CDH1 CTNNB1 KRAS MSH6 PTEN
11 11.31 FGFR2 KRAS PTEN
12 10.57 CDH1 CTNNB1
13 10.51 HOTAIR LINC-ROR

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 mismatch repair complex GO:0032300 8.8 MLH3 MSH3 MSH6

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell differentiation GO:0045603 9.55 CTNNB1 MIR200C
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 CTNNB1 KRAS
3 negative regulation of DNA recombination GO:0045910 9.52 MSH3 MSH6
4 regulation of osteoblast differentiation GO:0045667 9.51 CTNNB1 FGFR2
5 regulation of synaptic transmission, GABAergic GO:0032228 9.49 KRAS PTEN
6 morphogenesis of embryonic epithelium GO:0016331 9.48 CTNNB1 FGFR2
7 entry of bacterium into host cell GO:0035635 9.46 CDH1 CTNNB1
8 lung-associated mesenchyme development GO:0060484 9.43 CTNNB1 FGFR2
9 positive regulation of helicase activity GO:0051096 9.4 MSH3 MSH6
10 replication fork arrest GO:0043111 9.37 MSH3 MSH6
11 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 CTNNB1
12 maintenance of DNA repeat elements GO:0043570 9.26 MSH3 MSH6
13 meiotic mismatch repair GO:0000710 9.16 MSH3 MSH6
14 mesenchymal cell proliferation involved in lung development GO:0060916 8.96 CTNNB1 FGFR2
15 mismatch repair GO:0006298 8.92 MLH3 MSH3 MSH6 MUTYH

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 centromeric DNA binding GO:0019237 9.4 MLH3 MSH3
2 MutLalpha complex binding GO:0032405 9.37 MSH6 MUTYH
3 guanine/thymine mispair binding GO:0032137 9.32 MSH3 MSH6
4 single thymine insertion binding GO:0032143 9.26 MSH3 MSH6
5 single guanine insertion binding GO:0032142 9.16 MSH3 MSH6
6 mismatched DNA binding GO:0030983 9.13 MLH3 MSH3 MSH6
7 oxidized purine DNA binding GO:0032357 8.8 MSH3 MSH6 MUTYH

Sources for Endometrial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51